Compare ADMA Biologics Inc (ADMA) vs Agnico Eagle Mines Ltd (AEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Agnico Eagle Mines Ltd — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Agnico Eagle Mines Ltd trades at $183.53 (market cap $91.28B). The key difference: Agnico Eagle Mines Ltd is far larger — about 41.9× ADMA Biologics Inc's market cap, and Agnico Eagle Mines Ltd pays a 1% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AEM | |
|---|---|---|
Market Cap | $2.18B | $91.28B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $252.19 |
52-Week Low | $7.60 | $130.23 |
Enterprise Value | $2.25B | $88.12B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
AEM trades at $178.82, up 6.49% in the past 24 hours, reflecting strong momentum driven by record free cash flow and consistent earnings beats. The stock exhibits bullish technical signals with support at $177 and resistance at $181, while fundamentals show robust revenue growth to $11.91B in 2025 and a net income margin of 40.44%. Recent news highlights operational strength and gold price tailwinds.
Outlook remains positive with a consensus price target of $219.63, though risks include production costs and gold volatility. Analyst sentiment is strongly bullish with 21 buy ratings, supporting upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →
